Post-transfusion Platelet Count
- Conditions
- LeukemiaMultiple Sclerosis
- Interventions
- Biological: Platelet transfusion
- Registration Number
- NCT02601131
- Lead Sponsor
- Region Skane
- Brief Summary
The purpose of this study is to identify how the platelet count, complement system and endothelial markers are affected over time, after platelet transfusion in 4 different hematological patient groups.
- Detailed Description
Patients who are hospitalized at the Clinic for Hematology Diseases at the Skåne University Hospital (SUS) in Lund, Sweden with a central venous catheter or port-a-cath and should receive platelet transfusion due to thrombocytopenia are asked to participate in the study. Some patients who are being considered for platelet transfusions on several occasions will be able to attend more than one time in this study. After signed informed consent blood samples are drawn from the central line before, immediately after and then approximately. 1, 4, 8, 16 and 24 hours following the platelet transfusion. The platelet count (PLC) will then be taken daily following 4 days.
Sample size. Data from previous studies (Norol-98) shows that the PLC after platelet transfusion rises by 33 ± 25 x109/L (mean ± SD) 12 hours post-transfusion in patients with acute myeloid leukemia or pre-conditioning prior to bone marrow transplantation. The investigators want to show the same rise in the PLC after 12 hours with 80% power and 5% alpha risk of error for each group resulting in the sample size 13 per group and a total of 65 patients.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 80
- Patients admitted to the Clinic of Hematology Diseases, Skåne University Hospital, Lund, Sweden belonging to either of the groups described in paragraph 8 above and are prescribed platelet transfusion.
- Patients with aplastic anemia or treatment with antithymocyte globulin (ATG)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Autologous stem cell transplantation Platelet transfusion Patients undergoing autologous stem cell transplantation Platelet transfusion prophylaxis Platelet transfusion Patients receiving platelet transfusion prophylaxis before the intervention, such as insertion of a central venous catheter or lumbar puncture Allogeneic stem cell transplantation Platelet transfusion Patients undergoing allogeneic stem cell transplantation including both myeloablative conditioning (MAC) and the reduced-intensity conditioning (RIC) AML, ALL and MDS Platelet transfusion Patients receiving intensive chemotherapy with diagnoses of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) or myelodysplastic syndromes (MDS).
- Primary Outcome Measures
Name Time Method Change in platelet count after platelet transfusion 4 days after platelet transfusion
- Secondary Outcome Measures
Name Time Method Change in concentrations of complement factors in plasma after platelet transfusion 4 days after platelet transfusion Change in concentrations of complement factors in platelet rich plasma after platelet transfusion 4 days after platelet transfusion Change in concentrations of endothelial markers in plasma after platelet transfusion 4 days after platelet transfusion Analysis of platelets in platelet transfusions given to patients included in the study 4 days after platelet transfusion Flow cytometry of platelets in platelet transfusions given to patients included in the study
Trial Locations
- Locations (1)
Region Skåne
🇸🇪Lund, Sweden